Vamorolone
Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera
Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
June 20, 2023Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera
Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
